Your browser is no longer supported. Please, upgrade your browser.
HZNP Horizon Therapeutics Public Limited Company monthly Stock Chart
HZNP [NASD]
Horizon Therapeutics Public Limited Company
Index- P/E30.99 EPS (ttm)2.45 Insider Own0.80% Shs Outstand192.71M Perf Week20.25%
Market Cap13.74B Forward P/E18.03 EPS next Y4.21 Insider Trans-35.88% Shs Float172.35M Perf Month32.52%
Income517.40M PEG1.20 EPS next Q0.86 Inst Own94.30% Short Float3.83% Perf Quarter66.68%
Sales1.52B P/S9.05 EPS this Y736.30% Inst Trans2.68% Short Ratio2.42 Perf Half Y109.68%
Book/sh12.26 P/B6.19 EPS next Y55.37% ROA12.20% Target Price91.20 Perf Year174.88%
Cash/sh3.96 P/C19.13 EPS next 5Y25.90% ROE25.00% 52W Range23.81 - 78.93 Perf YTD109.50%
Dividend- P/FCF74.30 EPS past 5Y23.90% ROI18.70% 52W High-3.91% Beta1.15
Dividend %- Quick Ratio1.40 Sales past 5Y34.40% Gross Margin73.40% 52W Low218.52% ATR3.57
Employees1225 Current Ratio1.50 Sales Q/Q44.40% Oper. Margin4.40% RSI (14)75.60 Volatility7.69% 4.34%
OptionableYes Debt/Eq0.50 EPS Q/Q- Profit Margin34.10% Rel Volume1.32 Prev Close75.84
ShortableYes LT Debt/Eq0.42 EarningsAug 05 BMO Payout0.00% Avg Volume2.72M Price75.84
Recom1.70 SMA2021.39% SMA5034.80% SMA20089.64% Volume0 Change0.00%
Jan-08-20Initiated Goldman Neutral $35
Sep-26-19Initiated BofA/Merrill Buy $34
Sep-12-19Initiated Guggenheim Buy
Aug-14-19Upgrade BMO Capital Markets Market Perform → Outperform $29 → $36
May-01-19Upgrade Citigroup Neutral → Buy $21 → $32
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Feb-28-17Reiterated Mizuho Buy $25 → $22
Dec-16-16Upgrade Mizuho Neutral → Buy $14 → $25
Dec-09-16Downgrade Mizuho Buy → Neutral $30 → $14
Nov-28-16Upgrade Citigroup Neutral → Buy
Nov-08-16Reiterated Mizuho Buy $29 → $30
Oct-31-16Reiterated Mizuho Buy $33 → $29
Sep-13-16Reiterated Mizuho Buy $30 → $33
Aug-10-20 09:00AM  
Aug-09-20 09:10AM  
Aug-08-20 10:58AM  
Aug-06-20 11:20PM  
09:00AM  
Aug-05-20 04:01PM  
12:26PM  
07:46AM  
07:00AM  
Jul-31-20 07:00AM  
Jul-24-20 02:25PM  
Jul-22-20 08:00AM  
Jul-13-20 08:30AM  
Jul-09-20 08:30AM  
08:00AM  
Jul-08-20 10:00AM  
Jul-07-20 04:49PM  
Jul-01-20 09:00AM  
Jun-23-20 11:38AM  
Jun-03-20 08:05AM  
08:00AM  
May-30-20 01:06PM  
May-27-20 03:36PM  
May-21-20 09:15AM  
08:00AM  
May-19-20 08:00AM  
May-14-20 09:00AM  
May-11-20 12:00PM  
May-06-20 12:39PM  
10:43AM  
07:00AM  
Apr-27-20 08:10AM  
Apr-15-20 08:00AM  
Apr-09-20 09:00AM  
Apr-02-20 08:00AM  
Mar-31-20 12:00PM  
Mar-26-20 04:15PM  
Mar-22-20 10:13PM  
Mar-18-20 08:01AM  
Mar-17-20 02:04PM  
Mar-03-20 08:00AM  
Feb-28-20 10:00AM  
08:00AM  
Feb-27-20 08:00AM  
03:10AM  
Feb-26-20 07:00AM  
Feb-18-20 08:30AM  
08:00AM  
Feb-11-20 08:00AM  
Feb-06-20 10:51AM  
Feb-04-20 10:19AM  
08:00AM  
Jan-28-20 11:10AM  
Jan-27-20 12:10PM  
Jan-24-20 04:05PM  
Jan-23-20 11:40AM  
Jan-22-20 05:20PM  
10:03AM  
09:45AM  
Jan-21-20 03:04PM  
02:59PM  
Jan-18-20 09:08AM  
Jan-15-20 05:00AM  
Jan-14-20 07:55AM  
Jan-13-20 08:15AM  
08:05AM  
Jan-03-20 09:58AM  
Jan-02-20 08:34AM  
Dec-26-19 10:56AM  
Dec-20-19 11:40AM  
Dec-16-19 09:46AM  
08:40AM  
Dec-13-19 04:01PM  
07:11AM  
07:00AM  
Dec-09-19 08:00AM  
Dec-06-19 11:31AM  
Dec-04-19 11:27AM  
Dec-03-19 10:04AM  
Nov-25-19 09:35AM  
Nov-24-19 06:29PM  
Nov-22-19 08:00AM  
Nov-21-19 08:00AM  
Nov-14-19 09:30AM  
Nov-13-19 04:15PM  
Nov-11-19 02:05PM  
08:00AM  
05:57AM  
Nov-08-19 10:02AM  
09:30AM  
Nov-07-19 11:05AM  
Nov-06-19 08:45AM  
07:00AM  
Nov-05-19 08:00AM  
Nov-04-19 08:30AM  
08:00AM  
Oct-31-19 10:00AM  
Oct-30-19 10:33AM  
Oct-24-19 11:15AM  
09:30AM  
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walbert Timothy PChairman, President and CEOAug 06Sale72.54110,0007,979,414733,792Aug 07 05:42 PM
GREY MICHAEL GDirectorAug 05Option Exercise3.951,7556,9321,755Aug 07 05:40 PM
GREY MICHAEL GDirectorAug 05Sale73.351,755128,7290Aug 07 05:40 PM
Karnani VikramEVP & President, InternationalAug 03Option Exercise13.1536,772483,63678,941Aug 05 01:24 PM
SANTINI GINODirectorAug 03Option Exercise2.8835,795103,26235,795Aug 04 04:56 PM
GREY MICHAEL GDirectorJul 22Option Exercise3.951,7556,9321,755Jul 22 05:33 PM
GREY MICHAEL GDirectorJul 22Sale60.001,755105,3000Jul 22 05:33 PM
Kent JeffSee remarksJul 07Option Exercise5.6838,000215,98098,993Jul 07 06:57 PM
MOZE BARRYEVP, Chief Admin. OfficerJul 07Option Exercise13.1735,076461,918178,209Jul 07 06:50 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJul 06Sale57.509,100523,250278,797Jul 07 06:49 PM
MOZE BARRYEVP, Chief Admin. OfficerJul 01Sale54.6423,1581,265,441143,133Jul 02 04:46 PM
GREY MICHAEL GDirectorJun 25Option Exercise3.951,7556,9321,755Jun 26 05:00 PM
GREY MICHAEL GDirectorJun 25Sale55.001,75596,5250Jun 26 05:00 PM
Kent JeffSee remarksJun 10Sale48.052,785133,81960,993Jun 12 06:00 PM
Kent JeffSee remarksJun 01Sale49.9457,2152,857,17960,994Jun 02 06:18 PM
Karnani VikramEVP, Chief Commercial OfficerJun 01Sale50.232,369118,99542,169Jun 02 06:17 PM
Beeler Brian KEVP, General CounselJun 01Sale50.232,370119,04535,885Jun 02 06:16 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOMay 26Sale49.8521,9181,092,61234,834May 27 05:00 PM
GREY MICHAEL GDirectorMay 22Option Exercise7.8410,53082,55510,530May 26 05:00 PM
GREY MICHAEL GDirectorMay 22Sale48.7710,530513,5050May 26 05:00 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMay 11Option Exercise4.9633,479166,05647,445May 12 04:12 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMay 11Sale45.0033,4791,506,55513,966May 12 04:12 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 11Sale44.2249,1142,171,58530,816May 12 04:11 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 08Sale43.5145,3661,973,71179,930May 12 04:11 PM
DesJardin Michael A.EVP, Technical OperationsMay 07Option Exercise14.9323,159345,76464,359May 07 04:29 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffMay 06Option Exercise14.0559,794840,10695,183May 07 04:31 PM
Beeler Brian KEVP, General CounselMay 06Sale40.8048,0001,958,51537,206May 07 04:32 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffMay 06Sale41.1959,7942,462,91535,389May 07 04:31 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 06Sale41.193,545146,019129,095May 07 04:30 PM
DesJardin Michael A.EVP, Technical OperationsMay 06Sale41.5917,959747,00441,200May 07 04:29 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 05Sale37.005,007185,259132,640May 07 04:30 PM
DesJardin Michael A.EVP, Technical OperationsMay 05Sale38.008,980341,24059,159May 07 04:29 PM
Hoelscher Paul W.EVP, CFOMay 05Sale38.00104,9943,989,772132,501May 07 04:27 PM
Beeler Brian KEVP, General CounselApr 29Sale35.0215,880556,11885,206Apr 30 05:50 PM
Karnani VikramEVP, Chief Commercial OfficerApr 29Sale35.0015,683548,90543,489Apr 30 05:49 PM
Karnani VikramEVP, Chief Commercial OfficerApr 28Sale35.0130,0631,052,50659,172Apr 30 05:49 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffApr 20Sale34.1319,886678,68535,389Apr 21 05:00 PM
Beeler Brian KEVP, General CounselApr 16Sale32.519,000292,615101,086Apr 17 04:23 PM
Beeler Brian KEVP, General CounselApr 07Sale32.502979,653110,086Apr 08 04:46 PM
Beeler Brian KEVP, General CounselApr 06Sale32.502,37077,025110,383Apr 08 04:46 PM
MOZE BARRYEVP, Chief Admin. OfficerMar 30Option Exercise12.942,10627,252168,397Mar 31 05:01 PM
MOZE BARRYEVP, Chief Admin. OfficerMar 30Sale28.182,10659,347166,291Mar 31 05:01 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMar 11Option Exercise12.945,28768,41413,966Mar 13 04:15 PM
McHugh Miles WSr VP & Princ. Acctg OfficerFeb 27Sale34.341,00034,3420Feb 28 05:00 PM
Walbert Timothy PChairman, President and CEOFeb 21Sale35.2393,8643,306,829847,743Feb 21 08:07 PM
Walbert Timothy PChairman, President and CEOFeb 01Option Exercise0.009,086011,818Feb 04 04:14 PM
Kent JeffSee remarksJan 07Sale36.503,545129,393111,667Jan 07 06:30 PM
Karnani VikramEVP, Chief Commercial OfficerJan 06Sale35.629,297331,15978,146Jan 07 06:23 PM
Walbert Timothy PChairman, President and CEOJan 06Sale35.5784,8863,019,395903,309Jan 07 06:18 PM
Beeler Brian KEVP, General CounselDec 18Sale35.006,716235,06077,917Dec 20 04:46 PM
Beeler Brian KEVP, General CounselNov 25Sale32.519,969324,09384,633Nov 27 04:18 PM
McHugh Miles WSr VP & Princ. Acctg OfficerNov 14Option Exercise22.144,51699,984127,096Nov 15 04:19 PM
Beeler Brian KEVP, General CounselNov 05Sale30.0212,475374,46294,602Nov 07 04:38 PM
Walbert Timothy PChairman, President and CEOOct 15Option Exercise5.82311,8691,814,8791,097,165Oct 17 04:41 PM
Hoelscher Paul W.EVP, CFOOct 15Sale28.0120,000560,100139,310Oct 17 04:42 PM
Walbert Timothy PChairman, President and CEOOct 15Sale28.02320,1748,970,283776,991Oct 17 04:41 PM
Shannon James SamuelDirectorSep 13Option Exercise12.199,500115,8059,500Sep 13 06:52 PM
Shannon James SamuelDirectorSep 13Sale26.199,500248,8050Sep 13 06:52 PM
Shannon James SamuelDirectorSep 12Option Exercise12.1915,500188,94515,500Sep 13 06:52 PM
Shannon James SamuelDirectorSep 12Sale26.5915,500412,1310Sep 13 06:52 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffSep 12Sale26.7017,838476,27519,886Sep 13 06:51 PM
Hoelscher Paul W.EVP, CFOAug 30Sale28.001,35938,052159,310Sep 04 05:41 PM
Walbert Timothy PChairman, President and CEOAug 30Sale28.002,50070,000785,296Sep 04 05:34 PM
Hoelscher Paul W.EVP, CFOAug 22Option Exercise16.9029,576499,942160,669Aug 23 04:58 PM
Walbert Timothy PChairman, President and CEOAug 22Sale28.001,98455,552787,796Aug 23 04:57 PM
Hoelscher Paul W.EVP, CFOAug 21Sale28.0070,9031,985,426131,093Aug 23 04:58 PM
Walbert Timothy PChairman, President and CEOAug 21Sale28.0056,8361,591,518789,780Aug 23 04:57 PM